Get started
Author

Robyn Richardson

Observed names: R Richardson, R. Richardson
ORCID: 0000-0001-7865-183X
Observed ORCID: 0000-0001-7865-183X
OpenAlex ID: A5079247238
Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks
2014 · M Bloch, WWY Tong, et al. · HIV Medicine · 67
PDF
Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex With Men
2015 · Rosalind Foster, John McAllister, et al. · Clinical Infectious Diseases · 48
PDF
Dolutegravir with tenofovir disoproxil fumarate–emtricitabine as HIV postexposure prophylaxis in gay and bisexual men
2017 · John W. McAllister, Janet M. Towns, et al. · AIDS · 25
Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV
2018 · Jennifer F. Hoy, Robyn Richardson, et al. · AIDS · 23
Success and failure of initial antiretroviral therapy in adults
2018 · Andrew Carr, Robyn Richardson, et al. · AIDS · 18
PDF
Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults
2010 · Katherine Samaras, Robyn Richardson, et al. · AIDS · 17
Prolonged Effect of Zoledronic Acid on Bone Mineral Density and Turnover in HIV-Infected Adults on Tenofovir: A Randomized, Open-Label Study
2019 · Andrew Carr, Stephen J Kerr, et al. · Journal of Bone and Mineral Research · 15
PDF
Lower arterial stiffness and Framingham score after switching abacavir to tenofovir in men at high cardiovascular risk
2010 · Kate Sinn, Robyn Richardson, et al. · AIDS · 9
Predictors of severe and recurrent adult anaphylaxis, and gaps in the cascade of care: a retrospective, single‐centre study 2009–2018
2023 · Jacqueline Loprete, Jonathan Montemayor, et al. · Internal Medicine Journal · 7
Delabeling, safety, and impact of β-lactam allergy testing: A systematic review
2023 · Jacqueline Loprete, Robyn Richardson, et al. · Journal of Allergy and Clinical Immunology Global · 4
PDF
Standardized testing and written communication improve patient understanding of beta-lactam allergy testing outcomes: A multicenter, prospective study
2022 · Jacqueline Loprete, Constance H. Katelaris, et al. · Journal of Allergy and Clinical Immunology Global · 4
PDF
Switch to once-weekly, single-tablet islatravir–lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial
2026 · Amy E Colson, Princy N Kumar, et al. · The Lancet · 3
Socioeconomic and psychosocial factors are associated with poor treatment outcomes in Australian adults living with HIV: a case-control study
2019 · Krista J. Siefried, Stephen Kerr, et al. · Sexual Health · 3
PDF
Switch from tenofovir disoproxil fumarate to raltegravir is not associated with weight gain over 96 weeks
2019 · Mirella Carr, Robyn Richardson, et al. · AIDS · 2
Post-prandial lipid effects of raltegravir versus darunavir/ritonavir in HIV-1-infected adults commencing combination ART
2015 · F. J. Lee, D. Marriott, et al. · Journal of Antimicrobial Chemotherapy · 1
Early use of mepolizumab in DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome: A prospective multicenter, open-label, pilot study
2026 · James Yun, Robyn Richardson, et al. · Journal of the American Academy of Dermatology
Omalizumab Plus Peanut Oral Immunotherapy Treating Peanut Allergy in Adults: An Uncontrolled Clinical Trial
2025 · Jacqueline Loprete, Jonathan Montemayor, et al. · Clinical & Experimental Allergy
PDF
Peanut oral immunotherapy plus omalizumab for 24 weeks safely induces tolerance at 48 weeks in allergic adults (The OPAL Study)
2024 · Jacqueline Loprete, Jonathan Montemayor, et al.
Peanut oral immunotherapy plus omalizumab for 24 weeks safely induced tolerance at 48 weeks in allergic adults
2024 · Jacqueline Loprete, Jonathan Montemayor, et al. · Journal of Allergy and Clinical Immunology
Works count: 19
Citation count: 246
H-index: 8
I10-index: 7
Year
Topic
Type